Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 16Carcinoma, Non-Small-Cell Lung 13Neoplasms 9Colorectal Neoplasms 7Carcinoma, Hepatocellular 7Colonic Neoplasms 5Breast Neoplasms 5Adenocarcinoma 5Neoplasm Metastasis 4Lung Neoplasms 4Carcinoma, Renal Cell 4Urethral Neoplasms 3Rectal Neoplasms 3Liver Neoplasms 3Esophageal Neoplasms 3Urinary Bladder Neoplasms 2Ureteral Neoplasms 2Pancreatic Neoplasms 2Melanoma 2Malignant Solid Tumor 2Carcinoma, Transitional Cell 2Thymoma 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Solid Tumor 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Ovarian Neoplasms 1Non-small Cell Lung Cancer Metastatic 1

Interventions

Ramucirumab 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Gastroesophageal Cancer × Ramucirumab × Clear all
NCT02317991 2022-07-01

Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer

SCRI Development Innovations, LLC

Phase 2 Completed
65 enrolled 11 charts
Gastrointestinal

Gastroesophageal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡